RAPT Acquisition: A Timely Gambit

According to the official pronouncements emanating from the Securities and Exchange Commission – a body whose paperwork, one suspects, could circle the globe several times over – OrbiMed’s purchase brought their total holding in RAPT to a respectable 1,642,891 shares. This represented, at the quarter’s end, a valuation of $55.64 million. A not insignificant stake, even for a fund accustomed to shuffling millions about like cards in a particularly high-stakes game.








